DARWIN Precision is making strides in the biomedical industry, announcing mass production and shipment of its microneedle patches developed in partnership with LaunXP Biomedical to create a non-invasive drug delivery platform. In addition, DARWIN has introduced related biomedical testing technologies and is collaborating with biotech companies to develop water delivery drugs, fluorescence counters, and gas exposure systems, aiming for significant annual growth in biomedical-related revenue.
In recent years, DARWIN has actively expanded into medical and aesthetic fields, founding subsidiaries MicroDoctor Biomedical and Shine Biomed to develop microneedle technology and organ-on-a-chip products. These leverage DARWIN’s proprietary microstructure and electroforming techniques to simulate human organs for cancer drug testing, with results to be showcased at the July biotech exhibition.
Working with LaunXP, DARWIN co-developed the non-invasive drug delivery platform by combining LaunXP’s expertise in drug release design and microneedle material R&D with DARWIN’s precision microstructure manufacturing and automated mass production capabilities. This ensures consistent needle dimensions, uniform puncture force, and accurate drug loading during production, offering new medication delivery options for chronic disease treatment.
DARWIN’s microneedle patches are now in mass production and include products such as microneedle eye masks, acne patches, and combo masks. The company is applying its microstructure technology to develop microneedle patch rollers, initially targeting the medical aesthetics sector with whitening and anti-wrinkle skincare products, before expanding further into medical and pharmaceutical areas.
Looking ahead, DARWIN plans to integrate its microstructure and system integration expertise to develop biomedical and organ-on-a-chip testing components, instruments, and integrated systems. The goal is to deepen applications across different fields and advance microfluidic simulation technology, simultaneously developing chip and observation system equipment to provide downstream clients with one-stop services and shorten their new product development timelines.
In biomedical testing, DARWIN has introduced relevant technologies and partnered with biotech firms to develop water delivery drugs, fluorescence counters, and gas exposure systems.
At its recent shareholders’ meeting, DARWIN approved last year’s financial report and a cash capital reduction plan, along with the by-election of two directors. The capital reduction totaled approximately NT$665 million, representing 10%, with NT$1 returned per share to shareholders. Coupled with a proposed cash dividend of NT$0.25 per share, shareholders will receive a total of NT$1.25 per share in cash. After the capital reduction, DARWIN’s capital stock stands at NT$5.989 billion. The two new directors elected include General Manager Huang Sheng-Kai and Dr. Lu Rui-Mei, Deputy Director of the Biomedical Institute at the Industrial Technology Research Institute, who will serve as an independent director.
Resource: 達運進軍生醫報喜 微針貼片出貨
